Business Context and Reporting Period
This Form 6-K is filed by Adherex Technologies Inc. (noted as Fennec Pharmaceuticals Inc. in request metadata) on March 31, 2006. The filing serves to distribute the Company's annual report and press release containing consolidated financial statements and Management's Discussion and Analysis for the twelve-month fiscal period ended December 31, 2005.
Key Financial Metrics
The provided text is a cover sheet and exhibit index for the Form 6-K. It references the existence of financial statements but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibit 99.1 (Annual Report) and Exhibit 99.2 (Press Release), which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the annual report and press release for the fiscal year ended December 31, 2005.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, or specific risk factors. It notes the filing of a Notice of Annual General Meeting of Shareholders and a Management Proxy Circular (Exhibit 99.3). The filing includes a standard disclaimer stating that the information in this Form 6-K (including Exhibits 99.1 and 99.3) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) in the attached Exhibit 99.1 (Annual Report) and Exhibit 99.2 (Press Release), as they are not present in this summary text.
- Review the Management Proxy Circular (Exhibit 99.3) for details on the Annual General Meeting and corporate governance matters.
- Confirm the Company's legal name and status, noting the discrepancy between the request metadata ("Fennec Pharmaceuticals Inc.") and the filing header ("Adherex Technologies Inc.").
- Check the full Form 20-F filed with the SEC for the complete Management's Discussion and Analysis.